Dogwood Therapeutics, Inc.(DWTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DWTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Dogwood Therapeutics, Inc. (DWTX), a Healthcare sector company. DWTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Dogwood Therapeutics, Inc. reports net income of $-5.0M, free cash flow of $-4.6M. Top institutional holders of DWTX by reported 13-F value include ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. DWTX trades on the Nasdaq exchange and files with the SEC under CIK 1818844. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DWTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dogwood Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.0M
Free Cash Flow
Q1 2026
$-4.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-133.2% YoYOperating Income
-124.5% YoYEPS (Diluted)
-106911.1% YoYTotal Assets
+2164.1% YoYOp. Cash Flow
-80.5% YoY| Metric | FY 2024 | FY 2023 | FY 2019 |
|---|---|---|---|
| Net Income | $-12.3M -133.2% | $-5.3M | — |
| Operating Income | $-12.2M -124.5% | $-5.4M | — |
| EPS (Diluted) | $-0.96 -106911.1% | $-0.00 | — |
| Total Assets | $94.3M +2164.1% | $4.2M | — |
| Operating Cash Flow | $-8.8M -80.5% | $-4.9M | — |
AI Insight: DWTX Financial Trends
Dogwood remains pre-revenue with persistent operating losses, but equity swelled to $81M in Q1 2026 following Q4 2025 capital infusion.
• Equity rebounded sharply from $7M in Q3 2025 to $75M in Q4 2025, then $81M in Q1 2026, signaling significant financing event.
• Operating cash burn stabilized at $3–5M per quarter in Q3–Q4 2025 and Q1 2026, down from $6M in Q4 2024.
• Net losses remain volatile, ranging $4–16M quarterly, with Q3 2025 spike to $16M unexplained by visible operational metrics.
⚠ No revenue visibility across all eight quarters; runway dependent entirely on equity capital and burn trajectory.
⚠ Q3 2025 net loss of $16M and operating loss of $16M warrant explanation—material spike relative to adjacent quarters.
AI Insight: DWTX Ratio Trends
Dogwood remains deeply unprofitable, but return metrics stabilized in Q1 2026 after severe deterioration in Q3 2025.
• ROA improved to -20.9% in Q1 2026 from -68.5% in Q3 2025, signaling reduced asset drag or smaller quarterly losses.
• ROE and ROIC both stabilized near -24% to -25% range in Q4 2025 and Q1 2026, versus -20.2% ROE in Q4 2025.
⚠ Company remains loss-making across all profitability metrics; TTM ROIC at -35.5% and ROA at -29.7% reflect sustained negative returns.
⚠ Q3 2025 ROA plunged to -68.5%—worst quarter in dataset—suggesting operational or one-time headwind; monitor for recurrence.
Get alerted when DWTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Dogwood Therapeutics, Inc. including:
Top Institutional Holders of DWTX
ARMISTICE CAPITAL, LLC
$6.9M3,280,000 shVANGUARD CAPITAL MANAGEMENT LLC
$278.8K132,154 shGEODE CAPITAL MANAGEMENT, LLC
$167.6K79,434 shVANGUARD FIDUCIARY TRUST CO
$132.4K62,736 shNORTHERN TRUST CORP
$50.2K23,779 shGOLDMAN SACHS GROUP INC
$30.8K14,598 shMARSHALL WACE, LLP
$24.8K11,756 shTower Research Capital LLC (TRC)
$17.0K8,067 shUBS Group AG
$14.9K7,085 shActivest Wealth Management
$253.00120 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $6.9M | 3,280,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $278.8K | 132,154 |
| GEODE CAPITAL MANAGEMENT, LLC | $167.6K | 79,434 |
| VANGUARD FIDUCIARY TRUST CO | $132.4K | 62,736 |
| NORTHERN TRUST CORP | $50.2K | 23,779 |
| GOLDMAN SACHS GROUP INC | $30.8K | 14,598 |
| MARSHALL WACE, LLP | $24.8K | 11,756 |
| Tower Research Capital LLC (TRC) | $17.0K | 8,067 |
| UBS Group AG | $14.9K | 7,085 |
| Activest Wealth Management | $253.00 | 120 |
More Healthcare Companies
View all Healthcare →Put DWTX on your watchlist
Track score changes the day Dogwood Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DWTX a good stock to buy?
13F Pro's AI-powered analysis of Dogwood Therapeutics, Inc. (DWTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DWTX are available on the DWTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DWTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DWTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dogwood Therapeutics, Inc.'s investment landscape.